EUVIMEDEUVIMED entdecken
Open Access

Development of in vitro-in vivo correlation for establishing patient-centric quality standards of dissolution for lamotrigine extended-release tablets

Ahmed Zidan, Abu Bakar Siddique, Maha Shaklah, Om Anand, Thomas O'Connor, Muhammad Ashraf

European Journal of Pharmaceutics and Biopharmaceutics · 2025

DOI: 10.1016/j.ejpb.2025.114874 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2025. Verfasst von Ahmed Zidan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Office of Pharmaceutical Quality Research, OPQ, CDER, FDA, USA. Electronic address: ahmed.zidan@fda.hhs.gov. Hauptthemen laut MEDLINE: Lamotrigine, Anticonvulsants. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural FDA HHS, U.S. Department of Energy, U.S. Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In vitro-in vivo correlation (IVIVC) studies have been commonly used for assessing the impact of formulation and manufacturing changes on drug performance. The current study developed an IVIVC to establish patient-centric quality standards (PCQS) for dissolution using lamotrigine extended release (ER) 300 mg tablets as model formulation. Dissolution of Lamotrigine ER tablets was tested using various dissolution apparatus (USP II & III), dissolution media (biorelevant, non-bio relevant), media composition, pH, and hydrodynamics. The plasma lamotrigine concentration time profiles following oral administration were simulated using a physiologically based pharmacokinetic (PBPK) model. This PBPK model was developed and verified using plasma lamotrigine profiles following administration of lamotrigine intravenous (IV) solution and oral immediate-release (IR) tablets. Model verification results showed accurate prediction of Cmax and AUC following IV and IR lamotrigine administration with confidence level exceeding 95 %. Various IVIVC models were investigated using dissolution data of fast, medium, and slow ER lamotrigine 300 mg tablets manufactured in-house. Optimal IVIVC models were obtained using a second order polynomial and a two-compartment Loo-Riegelman deconvolution. The results of IVIVC goodness of fit showed that the dissolution condition in standard compendial media using USP apparatus II established a Level A IVIVC. This IVIVC model passed both internal and external validation criteria. Using these dissolution conditions, a PCQS of ≤10 % release at 2 h, ≤45 % at 6 h, and ≥80 % at 18 h was derived. In conclusion, this study demonstrates that a PCQS for lamotrigine ER tablets dissolution can be established using verified PBPK and validated IVIVC model and offers a reliable approach for assessment of product performance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LamotrigineAnticonvulsantsTabletsDelayed-Action PreparationsHumansSolubilityDrug LiberationAdministration, OralChemistry, PharmaceuticalModels, BiologicalQuality ControlArea Under Curve

Stichwörter der Autor:innen

DissolutionExtended releaseIn vitro-in vivo correlation (IVIVC)LamotriginePatient-centric quality standards (PCQS)Physiologically based pharmacokinetic (PBPK)

Substanzen

LamotrigineTabletsDelayed-Action PreparationsAnticonvulsants

Autor:innen und Institutionen

  • Office of Pharmaceutical Quality Research, OPQ, CDER, FDA, USA. Electronic address: ahmed.zidan@fda.hhs.gov.
  • Office of Pharmaceutical Quality Research, OPQ, CDER, FDA, USA.
  • Office of Clinical Pharmacology, OTS, CDER, FDA, USA.
  • Office of Pharmaceutical Quality Research, OPQ, CDER, FDA, USA. Electronic address: Muhammad.Ashraf@fda.hhs.gov.

Förderung

  • Intramural FDA HHS
  • U.S. Department of Energy
  • U.S. Food and Drug Administration
  • Oak Ridge Institute for Science and Education

Zitieren

APA

Zidan, A., Siddique, A. B., Shaklah, M., Anand, O., O'Connor, T., & Ashraf, M. (2025). Development of in vitro-in vivo correlation for establishing patient-centric quality standards of dissolution for lamotrigine extended-release tablets. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2025.114874

Vancouver

Zidan A, Siddique AB, Shaklah M, Anand O, O'Connor T, Ashraf M. Development of in vitro-in vivo correlation for establishing patient-centric quality standards of dissolution for lamotrigine extended-release tablets. European Journal of Pharmaceutics and Biopharmaceutics. 2025. doi:10.1016/j.ejpb.2025.114874

BibTeX
@article{Zidan2025,
  author = {Zidan, Ahmed and Siddique, Abu Bakar and Shaklah, Maha and Anand, Om and O'Connor, Thomas and Ashraf, Muhammad},
  title = {Development of in vitro-in vivo correlation for establishing patient-centric quality standards of dissolution for lamotrigine extended-release tablets},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2025},
  doi = {10.1016/j.ejpb.2025.114874}
}
Kostenlos starten →